Clinical Trial Of PPI In The Prophylaxis Of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis And Hyperamylasemia

BACKGROUND : Pancreatitis is the most common and serious complication of diagnostic and therapeutic ERCP. Uncertainties still exist about the clinical benefit of pharmacological prevention of post-ERCP pancreatitis by either antisecretory drugs such as somatostatin and its long-acting analogue octreotide, or protease inhibitors such as gabexate mesilate. The indiscriminate use of these drugs in all patients is unlikely to be cost-effective, but the selective use of prophylaxis for high-risk patients might be advocated. OBJECTIVES:To explore the prophylactic efect of proton pump inhibitor ( PPI)on post- endoscopic retrograde cholangiopancreatography pancreatitis, hyperamylasemia and other cormplications .METHODS: A total of 194patients were assigned into two groups given (n=113)or without(n=81) PPI after ERCP. RESULT: ERCP-related acute pancreatitis was clinically established in 5.4%and 4.8%, hyperamylasemia in 4h, 12h, 24h and 48h is 49.5%and 41.5%, 41.5%. 41.5%, 17.7%, 24.4%, 1.8%, 2.4%, of the patients In the above two groups, respectively (P>0.05). CONCLUSIONS: PPI infused after ERCP can not efectively prevent the occurrence of post-ERCP pancreatitis and hyperamylasemia.